Evidence map›Paper›PMID 39737874›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Multifaceted Immunomodulatory Nanocomplexes Target Neutrophilic-ROS Inflammation in Acute Lung Injury.

Fan Su, Chong Zhang, Qianyun Zhang, Yi Shen, Saiqi Li, Jianlin Shi, Ya-Xuan Zhu, Han Lin, Bin He

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Nutrients · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Ferrum@albumin assembled nanoclusters inhibit NF-Acta pharmaceutica Sinica. B · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fan SuDepartment of Critical Care Medicine and Emergency, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China.
Chong ZhangDepartment of Critical Care Medicine and Emergency, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China.
Qianyun ZhangDepartment of Critical Care Medicine and Emergency, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China.
Yi ShenDepartment of Critical Care Medicine and Emergency, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China.
Saiqi LiDepartment of Critical Care Medicine and Emergency, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China.
Jianlin ShiShanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, School of Medicine, Tongji University, Shanghai, 200072, P. R. China.
Ya-Xuan ZhuShanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, School of Medicine, Tongji University, Shanghai, 200072, P. R. China.
Han LinShanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, School of Medicine, Tongji University, Shanghai, 200072, P. R. China.ORCID https://orcid.org/0000-0003-1663-5468
Bin HeDepartment of Critical Care Medicine and Emergency, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China.

Funding

Chinese Academy of Sciences 2023262Clinical management optimization project of Shanghai Hospital Development SHDC22022207Fundamental Research Funds for the Central Universities YG2022ZD025Fundamental Research Funds for the Central Universities YG2023QNA40Fundamental Research Funds for the Central Universities YG2023QNB25Fundamental Research Funds for the Central Universities YG2024QNA52Key Discipline of Shanghai Municipal Health System 2023ZDFC0105National Natural Science Foundation of China 22205166National Natural Science Foundation of China 22422510National Natural Science Foundation of China 52372276National Natural Science Foundation of China 82272228Program of Shanghai Academic/Technology Research Leader 23XD1403500Shanghai Municipal Health Commission Talent Program 2002YQ022
6 · The paper itself

Abstract

The sepsis-induced acute lung injury (ALI) still represents one of the leading causes of death in critically ill patients, underscoring the need for novel therapies. Excessive activation of immune cells and damage of reactive oxygen species (ROS) are the main factors that exacerbate lung injury. Here, the multifaceted immunomodulatory nanocomplexes targeting the proinflammatory neutrophilic activation and ROS damage are established. The S100A8/9 inhibitor, ABR2575, is loaded in the nanocomplexes, which effectively blocks the neutrophils-S100A8/A9- toll-like receptors (TLRS)-Inflammasome signaling in ALI. Synergically, the SiH nanosheets are encapsulated together with ABR2575 into the core of poly(lactic-co-glycolic acid) (PLGA) nanosponges, to achieve sustainable hydrogen release for the alleviation of ROS-induced lung tissue injury, and also promote the M2 polarization of macrophages. This novel combination strategy is proven to significantly suppress the infiltration of neutrophils and pro-inflammatory macrophages into the lungs, decrease the activation of neutrophils and pro-inflammatory monocytes in the blood, facilitate the anti-inflammatory polarization of macrophages and monocytes, and reduce the expression of pro-inflammatory cytokines in both the lung and blood circulation, all of which alleviate the lung injuries in preclinical murine ALI models. The current investigations offer a novel nanomedicine for the treatment of ALI with great potential in clinical invention.

Indexed as

Acute Lung InjuryImmunomodulating AgentsNanoparticle Drug Delivery SystemNeutrophilsReactive Oxygen SpeciesAnimalsCalgranulin ACell LineFree Radical ScavengersHumansMaleMiceMice, Inbred C57BLModels, AnimalNanostructuresNeutrophil ActivationCalgranulin AFree Radical ScavengersImmunomodulating AgentsNanoparticle Drug Delivery SystemReactive Oxygen SpeciesS100A8 protein, humansilica hydrideSilicatesacute lung injuryhydrogen therapyneutrophilsreactive oxygen species

Identifiers

PMID39737874
PMCPMC11848588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.